Gianpaolo Marcacci

Emailg.marcacciistitutotumori.nait

Research activity per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Gianpaolo Marcacci is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

37 Article

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
Morabito, F., Zamagni, E., Conticello, C., Pavone, V., Palmieri, S., Bringhen, S., Galli, M., Mangiacavalli, S., Derudas, D., Rossi, E., Ria, R., Catalano, L., Tacchetti, P., Mele, G., Donatella Vincelli, I., Antonia Martino, E., Vigna, E., Botta, C., Bruzzese, A., Mele, A. & 30 others, Pantani, L., Rocchi, S., Garibaldi, B., Cascavilla, N., Ballanti, S., Tripepi, G., Frigeri, F., Pia Falcone, A., Cangialosi, C., Reddiconto, G., Farina, G., Barone, M., Rizzello, I., Musto, P., De Stefano, V., Musso, M., Teresa Petrucci, M., Offidani, M., Neri, A., Di Renzo, N., Di Raimondo, F., Boccadoro, M., Cavo, M., Gentile, M., Califano, C., Marcacci, G., Cerchione, C., Gamberi, B., Pompa, A. & Guarini, A., 2022, In: European Journal of Haematology. 108, 3, p. 178-189
Research output: Contribution to journal › Article › peer-review
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients: European Journal of Haematology
Morabito, F., Zamagni, E., Conticello, C., Pavone, V., Palmieri, S., Bringhen, S., Galli, M., Mangiacavalli, S., Derudas, D., Rossi, E., Ria, R., Catalano, L., Tacchetti, P., Mele, G., Donatella Vincelli, I., Antonia Martino, E., Vigna, E., Botta, C., Bruzzese, A., Mele, A. & 75 others, Pantani, L., Rocchi, S., Garibaldi, B., Cascavilla, N., Ballanti, S., Tripepi, G., Frigeri, F., Pia Falcone, A., Cangialosi, C., Reddiconto, G., Farina, G., Barone, M., Rizzello, I., Musto, P., De Stefano, V., Musso, M., Teresa Petrucci, M., Offidani, M., Neri, A., Di Renzo, N., Di Raimondo, F., Boccadoro, M., Cavo, M., Gentile, M., Califano, C., Giuliani, N., Attingenti, E., Lombardo, A., Antonioli, E., Marcacci, G., Amico, V., Capalbo, S., Cerchione, C., Belotti, A., Criscuolo, C., Bonalumi, A., Siniscalchi, A., Patriarca, F., Stocchi, R., Martino, M., Gangemi, D., Gagliardi, A., Gamberi, B., Quaresma, M., Pompa, A., Consoli, U., Uccello, G., Barilà, G., Staderini, M., Buda, G., Petrini, M., Furlan, A., Palazzo, G., Sabatelli, S., Mazza, P., Germano, C., Miccolis, R., Tarantini, G., Palumbo, G., Guarini, A., Cotzia, E., Innao, V., Mannina, D., Neri, S., Cardinale, G., Merenda, A., Maugeri, C., Poidomani, M., Longo, G., Carlisi, M., Svanera, G., Sica, A., Esposito, D., Fontana, R. & Sementa, A., 2021, In: Eur. J. Haematol..
Research output: Contribution to journal › Article › peer-review
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials
Gentile, M., Specchia, G., Derudas, D., Galli, M., Botta, C., Rocco, S., Conticello, C., Califano, C., Giuliani, N., Mangiacavalli, S., Attingenti, E., Lombardo, A., Brunori, M., Rossi, E., Antonioli, E., Ria, R., Zambello, R., Di Renzo, N., Mele, G., Marcacci, G. & 36 others, Musto, P., Capalbo, S., Cascavilla, N., Cerchione, C., Belotti, A., Criscuolo, C., Uccello, G., Curci, P., Vigna, E., Fraticelli, V., Vincelli, D., Bonalumi, A., Siniscalchi, A., Stocchi, R., Martino, M., Ballanti, S., Gangemi, D., Gagliardi, A., Gamberi, B., Pompa, A., Recchia, A. G., Tripepi, G., Pitino, A., Frigeri, F., Consoli, U., Bringhen, S., Zamagni, E., Patriarca, F., De Stefano, V., Di Raimondo, F., Palmieri, S., Petrucci, M. T., Offidani, M., Boccadoro, M., Cavo, M. & Morabito, F., 2021, In: Haematologica.
Research output: Contribution to journal › Article › peer-review
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials
Gentile, M., Specchia, G., Derudas, D., Galli, M., Botta, C., Rocco, S., Conticello, C., Califano, C., Giuliani, N., Mangiacavalli, S., Attingenti, E., Lombardo, A., Brunori, M., Rossi, E., Antonioli, E., Ria, R., Zambello, R., Di Renzo, N., Mele, G., Marcacci, G. & 36 others, Musto, P., Capalbo, S., Cascavilla, N., Cerchione, C., Belotti, A., Criscuolo, C., Uccello, G., Curci, P., Vigna, E., Fraticelli, V., Vincelli, D., Bonalumi, A., Siniscalchi, A., Stocchi, R., Martino, M., Ballanti, S., Gangemi, D., Gagliardi, A., Gamberi, B., Pompa, A., Recchia, A. G., Tripepi, G., Pitino, A., Frigeri, F., Consoli, U., Bringhen, S., Zamagni, E., Patriarca, F., De Stefano, V., Di Raimondo, F., Palmieri, S., Petrucci, M. T., Offidani, M., Boccadoro, M., Cavo, M. & Morabito, F., 2021, In: Haematologica. 106, 1, p. 291-294 4 p.
Research output: Contribution to journal › Article › peer-review
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials
Gentile, M., Specchia, G., Derudas, D., Galli, M., Botta, C., Rocco, S., Conticello, C., Califano, C., Giuliani, N., Mangiacavalli, S., Attingenti, E., Lombardo, A., Brunori, M., Rossi, E., Antonioli, E., Ria, R., Zambello, R., Di Renzo, N., Mele, G., Marcacci, G. & 36 others, Musto, P., Capalbo, S., Cascavilla, N., Cerchione, C., Belotti, A., Criscuolo, C., Uccello, G., Curci, P., Vigna, E., Fraticelli, V., Vincelli, D., Bonalumi, A., Siniscalchi, A., Stocchi, R., Martino, M., Ballanti, S., Gangemi, D., Gagliardi, A., Gamberi, B., Pompa, A., Recchia, A. G., Tripepi, G., Pitino, A., Frigeri, F., Consoli, U., Bringhen, S., Zamagni, E., Patriarca, F., De Stefano, V., Di Raimondo, F., Palmieri, S., Petrucci, M. T., Offidani, M., Boccadoro, M., Cavo, M. & Morabito, F., 2021, In: Haematologica. 106, 1, p. 291-294 4 p.
Research output: Contribution to journal › Article › peer-review

Gianpaolo Marcacci

Fingerprint

Network

Dive into details

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients: European Journal of Haematology

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials

Gianpaolo Marcacci

Fingerprint

Network

Research output

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients: European Journal of Haematology

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials